Which has higher earnings and valuation, VINC or AMPE?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A

Is VINC or AMPE more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Ampio Pharmaceuticals N/A N/A N/A

Is VINC or PTPI more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Petros Pharmaceuticals N/A -78.22% -23.50%

Which has higher earnings and valuation, VINC or ARDS?

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 0.00

Is VINC or ARDS more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Aridis Pharmaceuticals N/A N/A N/A

Do analysts prefer ADTX or VINC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, ADTX or VINC?

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt N/A N/A -$41.71M -$100.79 thousand N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is ADTX or VINC more profitable?

Vincerx Pharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Vincerx Pharma's return on equity of -248.33% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% Vincerx Pharma N/A -248.33% -132.73%

Which has higher earnings and valuation, SCPS or VINC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is SCPS or VINC more profitable?

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A Vincerx Pharma N/A -248.33% -132.73%

Vincerx Pharma (VINC) Competitors

$0.01 0.00 (-3.94%)

As of 09:30 AM Eastern

Compare

VINC vs. AMPE, PTPI, ARDS, ADTX, and SCPS

Should you buy Vincerx Pharma stock or one of its competitors? MarketBeat compares Vincerx Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vincerx Pharma include Ampio Pharmaceuticals (AMPE), Petros Pharmaceuticals (PTPI), Aridis Pharmaceuticals (ARDS), Aditxt (ADTX), and Scopus BioPharma (SCPS). These companies are all part of the "pharmaceutical products" industry.

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Ampio Pharmaceuticals	N/A	N/A	N/A

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Ampio Pharmaceuticals	Neutral

Vincerx Pharma has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, suggesting that its stock price is 496% more volatile than the broader market.

Summary

Vincerx Pharma and Ampio Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

In the previous week, Petros Pharmaceuticals had 1 more articles in the media than Vincerx Pharma. MarketBeat recorded 1 mentions for Petros Pharmaceuticals and 0 mentions for Vincerx Pharma. Vincerx Pharma's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Petros Pharmaceuticals	Neutral

Vincerx Pharma has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market.

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$1.64	N/A

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Summary

Petros Pharmaceuticals beats Vincerx Pharma on 7 of the 10 factors compared between the two stocks.

How does Vincerx Pharma compare to Aridis Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Aridis Pharmaceuticals	Neutral

Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.37, meaning that its share price is 4,837% more volatile than the broader market.

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	0.00

Aridis Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Aridis Pharmaceuticals	N/A	N/A	N/A

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Aridis Pharmaceuticals beats Vincerx Pharma on 6 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	N/A	N/A	-$41.71M	-$100.79 thousand	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

In the previous week, Aditxt had 3 more articles in the media than Vincerx Pharma. MarketBeat recorded 3 mentions for Aditxt and 0 mentions for Vincerx Pharma. Aditxt's average media sentiment score of 0.47 beat Vincerx Pharma's score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company	Overall Sentiment
Aditxt	Neutral
Vincerx Pharma	Neutral

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Aditxt has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vincerx Pharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Vincerx Pharma's return on equity of -248.33% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Vincerx Pharma	N/A	-248.33%	-132.73%

Summary

Vincerx Pharma beats Aditxt on 7 of the 11 factors compared between the two stocks.

How does Vincerx Pharma compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Scopus BioPharma has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

In the previous week, Scopus BioPharma had 1 more articles in the media than Vincerx Pharma. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Vincerx Pharma. Scopus BioPharma's average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Vincerx Pharma	Neutral

44.0% of Vincerx Pharma shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Vincerx Pharma	N/A	-248.33%	-132.73%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Summary

Scopus BioPharma beats Vincerx Pharma on 4 of the 7 factors compared between the two stocks.

Get Vincerx Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VINC vs. The Competition

Export

Metric	Vincerx Pharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$64K	$993.39M	$6.44B	$12.46B
Dividend Yield	N/A	4.84%	2.69%	5.22%
P/E Ratio	0.00	1.49	23.87	24.36
Price / Sales	N/A	125.49	521.52	117.01
Price / Cash	N/A	20.06	41.27	57.13
Price / Book	0.00	8.12	9.99	6.73
Net Income	-$40.16M	-$3.91M	$3.56B	$337.03M
7 Day Performance	N/A	-1.73%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	N/A	111.96%	28.76%	33.98%

Vincerx Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VINC Vincerx Pharma	N/A	$0.01 -3.9%	N/A	-74.1%	$64K	N/A	N/A	60
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
PTPI Petros Pharmaceuticals	N/A	$0.01 flat	N/A	-81.6%	$190K	$5.11M	N/A	20	Gap Up
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	+100.0%	$91K	N/A	0.02	30	Gap Down
ADTX Aditxt	1.3003 of 5 stars	$0.25 -50.6%	N/A	-100.0%	$17K	$14.34K	N/A	60	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VINC) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vincerx Pharma (VINC) Competitors

VINC vs. AMPE, PTPI, ARDS, ADTX, and SCPS

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Aridis Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Aditxt?

Summary

How does Vincerx Pharma compare to Scopus BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VINC vs. The Competition

Vincerx Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vincerx Pharma (VINC) Competitors

VINC vs. AMPE, PTPI, ARDS, ADTX, and SCPS

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Is VINC or AMPE more profitable?

Which has higher earnings and valuation, VINC or AMPE?

Do institutionals and insiders believe in VINC or AMPE?

Does the media refer more to VINC or AMPE?

Which has more volatility and risk, VINC or AMPE?

Summary

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Does the media favor VINC or PTPI?

Which has more risk & volatility, VINC or PTPI?

Do institutionals & insiders have more ownership in VINC or PTPI?

Which has better valuation & earnings, VINC or PTPI?

Is VINC or PTPI more profitable?

Summary

How does Vincerx Pharma compare to Aridis Pharmaceuticals?

Does the media favor VINC or ARDS?

Which has more volatility & risk, VINC or ARDS?

Which has higher earnings and valuation, VINC or ARDS?

Is VINC or ARDS more profitable?

Do insiders and institutionals have more ownership in VINC or ARDS?

Summary

How does Vincerx Pharma compare to Aditxt?

Which has better earnings and valuation, ADTX or VINC?

Does the media refer more to ADTX or VINC?

Do insiders & institutionals hold more shares of ADTX or VINC?

Which has more risk & volatility, ADTX or VINC?

Do analysts prefer ADTX or VINC?

Is ADTX or VINC more profitable?

Summary

How does Vincerx Pharma compare to Scopus BioPharma?

Which has more risk and volatility, SCPS or VINC?

Does the media prefer SCPS or VINC?

Do insiders & institutionals have more ownership in SCPS or VINC?

Is SCPS or VINC more profitable?

Which has higher earnings and valuation, SCPS or VINC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VINC vs. The Competition

Vincerx Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools